Last checked at 
16 Jul 2020 07:00
16 JULY 2020
BIOPHARMA CREDIT PLC
(THE "COMPANY")
COMPLETION OF SHARE BUYBACK PROGRAMME
Further to its announcement of 22 June 2020, BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, announces that its shares have traded at an average discount of 1% or less to the Net Asset Value per Ordinary Share over the most recent 2 week rolling period. Pursuant to the terms of the Prospectus, the Company will henceforth cease to repurchase its shares in the market as part of its discount control mechanism.
Since the activation of the discount control mechanism, as part of its Prospectus commitment the Company has repurchased a total of 59,694 shares representing 0.004% of its issued share capital as at 22 June.
Enquiries
BioPharma Credit plc
via Link Company Matters Limited
Company Secretary
+44 (0)1392 477 509
J.P. Morgan Cazenove
+44 (0)20 7742 4000
William Simmonds
Oliver Kenyon
Buchanan
+44 (0)20 7466 5000 / biopharmacredit@buchanan.uk.com
David Rydell
Mark Court
Jamie Hooper
Henry Wilson
Notes to Editors
BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
LEI: 213800AV55PYXAS7SY24